美国的关税威胁到印度的药品出口,有可能增加美国药品成本和供应中断。 US tariffs threaten India's pharmaceutical exports, risking higher drug costs and supply disruptions in the US.

印度制药公司担心美国关税会增加成本并扰乱其出口,它们供应近一半的美国非专利药物。 Indian pharmaceutical companies fear US tariffs could raise costs and disrupt their exports, which supply nearly half of US generic drugs. 全球第三大工业的目标是到2030年实现1 300亿美元的增长,这需要研发方面的预算支持和较简单的规章。 The industry, third-largest globally, aims for $130 billion growth by 2030, needing budget support for R&D and simpler regulations. 印度的药物在2022年节省了2,190亿美元,有可能加强美印卫生安全联系,实现药品供应链多样化,促进制造业。 India's drugs saved the US $219 billion in 2022, with potential for stronger US-India health security ties to diversify pharmaceutical supply chains and boost manufacturing.